Drug interactions
Arformoterol + Octreotide
Severity: Moderate
Arformoterol and Octreotide: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Octreotide can cause bradycardia and QT prolongation, and arformoterol, a long-acting beta-agonist, can cause tachycardia, hypokalemia and QT prolongation. Combined use may add to arrhythmia risk in susceptible patients.
What this interaction means in plain words
Arformoterol and Octreotide can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Arformoterol belongs to Respiratory; Octreotide belongs to Endocrine.
Why it happens
Additive effects on cardiac repolarization, with beta-agonist-induced hypokalemia increasing susceptibility.
What to do
Monitor ECG and serum potassium in patients with cardiac disease, electrolyte abnormalities or other QT-prolonging drugs. Correct hypokalemia and hypomagnesemia.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Arformoterol and Octreotide, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Octreotide
Other interactions of Arformoterol
Frequently asked questions
Can I take Arformoterol with Octreotide?
MediHelp rates the interaction as moderate. Arformoterol and Octreotide can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Octreotide can cause bradycardia and QT prolongation, and arformoterol, a long-acting beta-agonist, can cause tachycardia, hypokalemia and QT prolongation. Combined use may add to arrhythmia risk in susceptible patients.
How serious is the interaction between Arformoterol and Octreotide?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor ECG and serum potassium in patients with cardiac disease, electrolyte abnormalities or other QT-prolonging drugs. Correct hypokalemia and hypomagnesemia.
What other medicines interact with Octreotide?
MediHelp also lists interactions of Octreotide with, for example, Adagrasib, Amisulpride, Arsenic trioxide. The full list is on the Octreotide page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
